Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment?
| dc.authorid | Gök, Murat/0000-0003-3118-9064 | |
| dc.authorwosid | Gök, Murat/AAZ-3324-2021 | |
| dc.contributor.author | Yalta, Kenan | |
| dc.contributor.author | Gok, Murat | |
| dc.contributor.author | Ozturk, Cihan | |
| dc.contributor.author | Yalta, Tulin | |
| dc.date.accessioned | 2024-06-12T11:22:37Z | |
| dc.date.available | 2024-06-12T11:22:37Z | |
| dc.date.issued | 2022 | |
| dc.department | Trakya Üniversitesi | en_US |
| dc.description.abstract | [Abstract Not Available] | en_US |
| dc.identifier.doi | 10.33963/KP.a2022.0166 | |
| dc.identifier.endpage | 959 | en_US |
| dc.identifier.issn | 0022-9032 | |
| dc.identifier.issn | 1897-4279 | |
| dc.identifier.issue | 9 | en_US |
| dc.identifier.pmid | 35833474 | en_US |
| dc.identifier.scopus | 2-s2.0-85139571772 | en_US |
| dc.identifier.scopusquality | Q3 | en_US |
| dc.identifier.startpage | 958 | en_US |
| dc.identifier.uri | https://doi.org/10.33963/KP.a2022.0166 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14551/25990 | |
| dc.identifier.volume | 80 | en_US |
| dc.identifier.wos | WOS:000876199400001 | en_US |
| dc.identifier.wosquality | Q2 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.indekslendigikaynak | Scopus | en_US |
| dc.indekslendigikaynak | PubMed | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Polish Cardiac Soc-Polskie Towarzystwo Kardiologiczne | en_US |
| dc.relation.ispartof | Kardiologia Polska | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | [No Keywords] | en_US |
| dc.title | Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment? | en_US |
| dc.type | Letter | en_US |
